Maintenance after therapy for recurrence: Treatment to control disease after complete or partial response to therapy
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
Maintenance after therapy for recurrence: Treatment to control disease after complete or partial response to therapy
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Standard of Care Targeted Drugs | |||||
| DNA Damage Repair Pathway Inhibitors: PARP | NCT01874353; SOLO-2 | III | Olaparib Prescribing Information | Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy (SOLO-2) | Improved PFS and OS with olaparib maintenance treatment in gBRCA MUT patients Ola vs Placebo: PFS: 19.1 vs 5.5 months* pub 2017, pub 2021 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT01847274; NOVA | III | Niraparib Prescribing Information | A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer (NOVA) | Improved PFS for gBRCA MUT patients with niraparib maintenance; the benefit of niraparib maintenance therapy extends beyond first progression Nir vs Placebo: gBRCA MUT: pub 2016, pub 2019, abs Mar 2021 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT01968213; ARIEL3 | III | Rucaparib Prescribing Information | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3) | Improved PFS and PFS2 in BRCA MUT patients, but no OS benefit with rucaparib maintenance Ruc vs Placebo: BRCA MUT: pub 2017, pub 2020, abs Jun 2021 and poster, pub 2021, abs Oct 2022 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT00753545; Study 19 | II | Olaparib Prescribing Information | Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens (Study 19) | Improved PFS and OS with olaparib maintenance Ola vs Placebo: All: pub 2012; 2014; 2016 |
| Drugs in Clinical Development | |||||
| DNA Damage Repair Pathway Inhibitors: PARP | NCT01847274; NOVA | III | Niraparib | A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer (NOVA) | Improved PFS for all patients with niraparib maintenance with greatest activity in BRCA MUT patients; the benefit of niraparib maintenance therapy extends beyond first progression Nir vs Placebo: non-gBRCA MUT: pub 2016, pub 2019, abs Mar 2021 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT01968213; ARIEL3 | III | Rucaparib | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3) | Improved PFS and PFS2, but no OS benefit for all patients with rucaparib maintenance Ruc vs Placebo: All: pub 2017, pub 2020, abs Jun 2021 and poster, pub 2021, abs Oct 2022 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT03106987; OReO/ENGOT Ov-38 | III | Olaparib | A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy | Rechallenge with maintenance olaparib following response to Pt-based therapy provides a significant improvement in PFS vs placebo, irrespective of BRCA status Ola vs Placebo: non-BRCA MUT: abs Sept 2021 |